Sana Biotechnology Q3 2026 Results: Turns Profitable, Net Income $20.4M
Sana Biotechnology reported a net loss of $90.4 million for the nine months ended September 30, 2026, a significant improvement from the $185.3 million loss in the prior year period. The company achieved a net income of $20.4 million in the third quarter of 2026, primarily driven by a $63.4 million gain from the revaluation of research and development related success payments and contingent consideration.
- Key figure
- Net income $20.4M